Clostridium butyricum M588- Miyarisan Pharmaceutical
Alternative Names: Clostridium butyricum Miyairi 588 strain; C. butyricum CBM 588 Probiotic Strain; C. butyricum MIYAIRI Strain; C. butyricum Strain MIYAIRI 588; CBM-588; Cdactin-O; CM588; Miya-BM; MIYAIRI 588 Strain of C. butyricumLatest Information Update: 17 Jul 2025
At a glance
- Originator Miyarisan Pharmaceutical
- Developer Osel Inc
- Class Antidiarrhoeals; Antineoplastics; Probiotics
- Mechanism of Action Gastrointestinal microbiome modulators; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diarrhoea
- Phase I Renal cancer
Most Recent Events
- 19 Jun 2024 Phase-I clinical trials in Renal cancer (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT06399419)
- 16 Jun 2015 Phase II development is ongoing in the USA
- 04 Nov 2009 Clinical development is ongoing in USA